Baseline characteristics and comparison based on initial treatment modality.

Baseline characteristics and comparison based on initial treatment modality.</p

Risk factors for overall survival.

Risk factors for overall survival.</p

Overall survival according to initial treatment modality in hepatocellular carcinoma patients with extrahepatic spread.

Abbreviation: TACE, transarterial chemoembolization.</p

Initial and subsequent treatment according to initial treatment modality.

Initial and subsequent treatment according to initial treatment modality.</p

Overall survival by initial treatment modality (transarterial chemoembolization vs. sorafenib) according to pre-defined subgroups.

Overall survival by initial treatment modality (transarterial chemoembolization vs. sorafenib) according to pre-defined subgroups.</p

Factors associated with survival.

<p>HR, hazard ratio; HBV, hepatitis B virus; AFP, alphafetoprotien.</p><p>Multivariate model included etiology (HBV vs. non-HBV), tumor size, portal vein invasion, extrahepatic spread and AFP levels.</p><p>Factors associated with survival.</p

Cumulative incidence of an inactive carrier according to hepatitis B virus (HBV) DNA and quantitative hepatitis B surface antigen (qHBsAg) levels in patients without cirrhosis.

<p>Those with low qHBsAg and low HBV DNA levels showed higher cumulative incidence of an inactive carrier during follow-up period. A-D represent for low HBV DNA plus low qHBsAg levels (A), low HBV DNA plus high qHBsAg levels (B), high HBV DNA plus low qHBsAg levels (C), and high HBV DNA plus high qHBsAg levels (D), respectively. The cut-off level to define low vs. high was 20,000 IU/ml for HBV DNA and 2,500 IU/ml for qHBsAg.</p

Baseline characteristics.

<p>^*Initial alphafetoprotein level was missing in 38 patients.</p><p>^†Of the 160 patients with distant metastasis, 33 patients (20.6%) had concomitant nodal metastasis.</p><p>Baseline characteristics.</p

Survival by treatment modalities.

<p>^*Adjusted for age, gender, Child-Pugh class.</p><p>Survival by treatment modalities.</p

Survival by treatment modalities in each sub-stage.

<p>HR, hazard ratio; CI, confidence interval; TACE, transarterial chemoembolization.</p><p>^*Adjusted for age, gender, Child-Pugh class.</p><p>^†Patients who received experimental therapy were excluded.</p><p>Survival by treatment modalities in each sub-stage.</p